CORRESP Filing
Phio Pharmaceuticals Corp.
Date: Dec. 1, 2025 · CIK: 0001533040 · Accession: 0001683168-25-008768
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-291667
Letter
VIA EDGAR Office of Life Sciences Division of Corporation Finance Registration Statement on Form S-3 Filed November 20, 2025 File No. 333-291667 Request for Acceleration of Effective Date
Dear Mr. Campbell:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Phio Pharmaceuticals Corp. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on December 3, 2025, or as soon thereafter as possible.
Please direct any questions or comments concerning this request to Lisa Carson of Phio Pharmaceuticals Corp. at (610) 310-1726. Also, please notify Ms. Carson when this request for acceleration has been granted.
Very truly yours,
PHIO PHARMACEUTICALS CORP.
Show Raw Text
CORRESP 1 filename1.htm PHIO PHARMACEUTICALS CORP. 411 Swedeland Road, Suite 23-1080 King of Prussia, PA 19406 December 1, 2025 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell Re: Phio Pharmaceuticals Corp. Registration Statement on Form S-3 Filed November 20, 2025 File No. 333-291667 Request for Acceleration of Effective Date Dear Mr. Campbell: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Phio Pharmaceuticals Corp. hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-3 and declare such Registration Statement effective as of 4:00 p.m., Eastern Time, on December 3, 2025, or as soon thereafter as possible. Please direct any questions or comments concerning this request to Lisa Carson of Phio Pharmaceuticals Corp. at (610) 310-1726. Also, please notify Ms. Carson when this request for acceleration has been granted. Very truly yours, PHIO PHARMACEUTICALS CORP. By: /s/ Robert J. Bitterman Name: Robert J. Bitterman Title: President and Chief Executive Officer cc: Lisa Carson, Phio Pharmaceuticals Corp.